These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 2867148)

  • 1. The effect of bezafibrate on hyperlipidaemia in experimental nephrotic syndrome in rats.
    Williams AJ; Baker FE; Walls J
    J Pharm Pharmacol; 1985 Oct; 37(10):741-3. PubMed ID: 2867148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual bezafibrate-simvastatin therapy for combined hyperlipidaemia.
    Hutchesson AC; Moran A; Jones AF
    J Clin Pharm Ther; 1994 Dec; 19(6):387-9. PubMed ID: 7876371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypocholesterolemic effect of spirulina in patients with hyperlipidemic nephrotic syndrome.
    Samuels R; Mani UV; Iyer UM; Nayak US
    J Med Food; 2002; 5(2):91-6. PubMed ID: 12487756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicity of lovastatin in rats with experimentally induced nephrotic syndrome.
    Joven J; Vilella E; Camps J; Masana L; Turner PR; Simó JM; Villabona C
    Nephron; 1990; 56(4):399-404. PubMed ID: 2079999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of vegetarian soy diet on hyperlipidaemia in nephrotic syndrome.
    D'Amico G; Gentile MG; Manna G; Fellin G; Ciceri R; Cofano F; Petrini C; Lavarda F; Perolini S; Porrini M
    Lancet; 1992 May; 339(8802):1131-4. PubMed ID: 1349366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of probucol on hyperlipidemia in patients with nephrotic syndrome.
    Iida H; Izumino K; Asaka M; Fujita M; Nishino A; Sasayama S
    Nephron; 1987; 47(4):280-3. PubMed ID: 3696330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of lovastatin and bezafibrate on cyclosporine-induced hyperlipidemia in rabbits.
    Hidalgo L; López-Miranda J; Espino A; Alcala J; Blanco J; Prada JL; Rodríguez M; Jiménez-Perepérez JA; Jansen S; Pérez-Jiménez F
    Transplant Proc; 1995 Apr; 27(2):1857-61. PubMed ID: 7725532
    [No Abstract]   [Full Text] [Related]  

  • 8. Improvement of hyperlipidaemia by bezafibrate treatment in RDT patients.
    Grützmacher P; Scheuermann E; Lang W
    Proc Eur Dial Transplant Assoc; 1981; 18():169-75. PubMed ID: 7036147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effects of bezafibrate on in vivo VLDL-triglyceride production in the rat.
    Kazumi T; Yoshino G; Iwai M; Matsuba K; Matsushita M; Iwatani I; Kasama T; Yoshida M; Baba S
    Diabetes Res Clin Pract; 1990; 9(2):163-8. PubMed ID: 2198155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acyl-coenzyme A:cholesterol acyltransferase inhibition ameliorates proteinuria, hyperlipidemia, lecithin-cholesterol acyltransferase, SRB-1, and low-denisty lipoprotein receptor deficiencies in nephrotic syndrome.
    Vaziri ND; Liang KH
    Circulation; 2004 Jul; 110(4):419-25. PubMed ID: 15262831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effect of lovastatin on lipoprotein profile in patients with primary nephrotic syndrome.
    Prata MM; Nogueira AC; Pinto JR; Correia AM; Vicente O; Rodrigues MC; Miguel MJ
    Clin Nephrol; 1994 May; 41(5):277-83. PubMed ID: 8050207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of bezafibrate on serum lipids in normo- and spontaneously hyperlipidemic rats.
    Pill J; Wolff S; Stegmeier K; Schmidt FH
    Methods Find Exp Clin Pharmacol; 1988 Aug; 10(8):487-92. PubMed ID: 3226219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased high density lipoprotein cholesterol in adult nephrotic syndrome in Nigeria.
    Adigun MO; Agbedana EO; Kadiri S; Taylor GO
    Afr J Med Med Sci; 1999; 28(1-2):97-100. PubMed ID: 12953996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lovastatin versus bezafibrate for hyperlipemia treatment after heart transplantation.
    Hidalgo L; Zambrana JL; Blanco-Molina A; López-Granados A; Concha M; Casares J; Jiménez-Pérez J; López-Miranda J; Pérez-Jiménez F
    J Heart Lung Transplant; 1995; 14(3):461-7. PubMed ID: 7654731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia.
    Monk JP; Todd PA
    Drugs; 1987 Jun; 33(6):539-76. PubMed ID: 3301301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between simvastatin and bezafibrate in effect on plasma lipoproteins and apolipoproteins in primary hypercholesterolaemia.
    Schulzeck P; Bojanovski M; Jochim A; Canzler H; Bojanovski D
    Lancet; 1988 Mar; 1(8586):611-3. PubMed ID: 2894548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacological investigation of bezafibrate, a hypolipidemic agent (1). Effects of bezafibrate on normal and experimental hyperlipidemia in rats].
    Kusama H; Nishiyama M; Ikeda S
    Nihon Yakurigaku Zasshi; 1988 Sep; 92(3):175-80. PubMed ID: 3243507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome.
    Rabelink AJ; Hené RJ; Erkelens DW; Joles JA; Koomans HA
    Lancet; 1988 Dec; 2(8624):1335-8. PubMed ID: 2904053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy and safety of ciprofibrate and sustained-release bezafibrate in patients with type II hyperlipidaemia.
    Betteridge DJ; O'Bryan-Tear CG
    Postgrad Med J; 1996 Dec; 72(854):739-43. PubMed ID: 9015467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.
    Goa KL; Barradell LB; Plosker GL
    Drugs; 1996 Nov; 52(5):725-53. PubMed ID: 9118820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.